ReviewStem cell reviews2005
Liver stem cells: implications for hepatocarcinogenesis.
Review in Stem cell reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 4 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Pooled it
- HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis.BioMed research international · 2016Pooled it
- CD24 single nucleotide polymorphisms and cancer risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis.BMC cancer · 2012Pooled it
- Long-Term Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma After Liver Transplantation in Patients with or without Concurrent Hepatocellular Carcinoma.Annals of transplantation · 2025Article
- A case of an alpha-fetoprotein-producing intrahepatic cholangiocarcinoma.Clinical journal of gastroenterology · 2025Review
- Transarterial Chemoembolization Following Curative Resection May Not Improve Survival for Hepatitis B Virus Associated Intrahepatic Cholangiocarcinoma: Propensity Score Weighting Analysis.Journal of hepatocellular carcinoma · 2025Article
- LIN28 and histone H3K4 methylase induce TLR4 to generate tumor-initiating stem-like cells.iScience · 2023Article
- Review
- Pathogenesis to management of hepatocellular carcinoma.Genes & cancer · 2022Review
- HCV and tumor-initiating stem-like cells.Frontiers in physiology · 2022Review
- Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.Bioengineered · 2021Article
- Nondegradable Collagen Increases Liver Fibrosis but Not Hepatocellular Carcinoma in Mice.The American journal of pathology · 2021Article
- Predictive Value of Interferon γ Receptor Gene Polymorphisms for Hepatocellular Carcinoma Susceptibility.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- The cellular origins of cancer with particular reference to the gastrointestinal tract.International journal of experimental pathology · 2020Review
- Cell fate, metabolic reprogramming and lncRNA of tumor-initiating stem-like cells induced by alcohol.Chemico-biological interactions · 2020Review
- A Rare Colonic Metastasis Case from Hepatocellular Carcinoma.Open access Macedonian journal of medical sciences · 2019Article
- Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma after resection.Cancer medicine · 2019Article
- Methionine adenosyltransferases in liver cancer.World journal of gastroenterology · 2019Review
- Oncogenic Signaling Induced by HCV Infection.Viruses · 2018Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous studies point to the fact that liver tumors are derived from single cells (monoclonal), but the important question is, which cell? Stem cell biology and cancer are inextricably linked. In continually renewing tissues such as the intestinal mucosa and epidermis, in which a steady flux of cells occurs from the stem cell zone to the terminally differentiated cells that are imminently to be lost, it is widely accepted that cancer is a disease of stem cells, as these are the only cells that persist in the tissue for a sufficient length of time to acquire the requisite number of genetic changes for neoplastic development. In the liver the identity of the founder cells for the two major primary tumors, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), is more problematic. The reason for this is that no such obvious unidirectional flux occurs in the liver, though it is held that the centrilobular hepatocytes may be more differentiated (polyploid) and closer to cell senescence than those cells closest to the portal areas. Moreover the existence of bipotential hepatic progenitor cells (HPCs), along with hepatocytes endowed with longevity and long-term repopulating potential suggests there may be more than one type of carcinogen target cell. Irrespective of which target cell is involved, cell proliferation at the time of carcinogen exposure is pivotal for "fixation" of the genotoxic injury into a heritable form. Taking this view, any proliferative cell in the liver can be susceptible to neoplastic transformation. Thus, hepatocytes are implicated in many instances of HCC, direct injury to the biliary epithelium implicates cholangiocytes in some cases of CC, whereas HPC/oval cell activation accompanies very many instances of liver damage irrespective of etiology, making such cells very likely carcinogen targets. Of course, we must qualify this assertion by stating that many carcinogens are both cytotoxic and cytostatic, and that HPC proliferation may be merely a bystander effect of this toxicity. An indepth discussion of causes of cancer in the liver are beyond the scope of this review, but infectious agents (e.g., hepatitis B and C viruses) play a major role, not just in transactivating or otherwise disrupting cellular proto-oncogenes (hepatitis B virus [HBV]), but in also causing chronic inflammation (hepatitis C virus [HCV] and HBV). Sustained epithelial proliferation in a milieu rich in inflammatory cells, growth factors, and DNA-damaging agents (reactive oxygen and nitrogen species produced to fight infection), will lead to permanent genetic changes in proliferating cells. The upregulation of the transcription factor nuclear factor kappaB (NF-kappaB) in transformed hepatocytes, through the paracrine action of tumor necrosis factor-alpha from neighboring endothelia and inflammatory cells, may be critical for tumor progression given the mitogenic and anti-apoptotic properties of proteins encoded by many of NF-kappaB's target genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.